← Eichor
Study identifier: NCT04975646 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Goal Attainment Scaling in Upper Limb Spasticity Treatment

Condition: Ischemic Stroke · Hemorrhagic Stroke  ·  Sponsor: University Rehabilitation Institute, Republic of Slovenia

PhaseNA
Planned participants70
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Patients after stroke with upper limb spasticity treated with botulinum toxin-A (BTX-A) will be included in this two-part study. In the first part, goal attainment scaling and comprehensive assessment of motor functioning will be performed before BTX-A application and after two weeks. In the second part, the patients will be randomised into a test group performing prescribed regular exercise for two weeks and a control group exercising at their own discretion during the same period, whereby the patients' health-related quality of life will be assessed at the beginning and end of the two-week period.

This description comes directly from the study's public registry record.

Talk to the study team

Metka Moharić, MD, PhD  ·  +386 1 4758441  ·  metka.moharic@ir-rs.si

Always discuss trial participation with your own doctor first.

Locations (1)

University Rehabilitation Institute, Republic of SloveniaLjubljana, SloveniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04975646